FIFTH CONFERENCE ON RADIOIMMUNODETECTION AND RADIOIMMUNOTHERAPY OF CANCER

December 1, 1995 Supplement
Volume 55 • Number 23
PP. 5703s-5990s
ISSN 0008-5472 • CNREA 8
FIFTH CONFERENCE ON
RADIOIMMUNODETECTION
AND RADIOIMMUNOTHERAPY
OF CANCER

Held at the Princeton Marriott
Forrestal Village
Princeton, New Jersey
October 6-8, 1994

Sponsored by the Center for Molecular Medicine and Immunology
and the Garden State Cancer Center

Program Committee
Donald J. Buchsbaum
Gerard L. DeNardo
David M Goldenberg (Chairman)
Donald J. Hnatowich
Susan J. Knox
Steven M. Larson
Claude F. Meares
Ralph A. Reisfeld
Jeffrey Schom (Co-Chairman)
Margaret A. Tempeo
Barry W. Wessels

Supplement Editor
David M. Goldenberg

Technical Editor
Michael J. Beveridge

This conference was supported in part by Pharmacia-Adria, Dublin, OH; National Cancer Institute, NIH, Bethesda, MD (Grant # R 13 CA 63744-01); Immunomedics, Inc., Morris Plains, NJ; Immunex Research and Development Corporation, Seattle, WA; Organon Bioteknika/Biotechnology Research Institute, Rockville, MD; and Idec Pharmaceuticals Corporation, San Diego, CA.
generosity of the corporate sponsors identified herein, as well as a conference grant from the National Cancer Institute. Finally, I thank the participants and authors who are responsible for the most important aspect of the conference and these proceedings, the scientific content.

References

COVER LEGEND

Shown are anterior (A) and posterior (B) whole-body scans from Figure 3 of the article by Juweid et al., “Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with 131I-labeled monoclonal antibodies to carcinoembryonic antigen,” found in this Supplement (pp. 5946s–5951s). Both diffuse and focal sites of medullary thyroid cancer were localized by a radiolabeled antibody to carcinoembryonic antigen, depicting the extent of disease in this patient by means of a single imaging study.